Reduction of myocardial infarct size in vivo by carbohydrate-based glycomimetics.
One of the foremost mechanisms involved in the pathogenesis of myocardial reperfusion injury is the adhesion of neutrophils within the myocardium. The initial neutrophil-endothelial cell interactions are mediated by the selectin family of adhesion molecules. Blockade of this group of adhesion molecules, through the use of synthetic carbohydrate analogs to the selectin ligand sialyl Lewisx and glycomimetics, has been beneficial in reducing neutrophil influx and infarct size. In the present study, glycyrrhizin (GM1292), a natural structural glycomimetic, was analyzed for the ability to decrease myocardial infarct size after regional myocardial ischemia/reperfusion. To determine the structural requirements for optimal cardioprotective activity, two additional compounds related to glycyrrhizin, GM3290 and GM1658 (glycyrrhetinic acid), were studied. The molecular structures of the latter two compounds differ in the number of glucuronic acid residues in their respective molecules. Open-chest, anesthetized rabbits were subjected to 30 min occlusion of the left coronary artery followed by 5 hr of reperfusion. Vehicle or glycomimetic (10 mg/kg/hr) was administered intravenously immediately before the onset of reperfusion and every hour during the reperfusion period. Myocardial infarct size in rabbits treated with GM1292 (two glucuronic acid residues) and GM3290 (one glucuronic acid residue) was reduced significantly when compared with vehicle-treated animals (P < .05). GM1658, which lacks glucuronic acid residues, did not provide a protective effect in vivo. The data suggest that GM1292 and GM3290, which contain carbohydrate moieties, are effective in reducing the degree of myocardial injury after an acute period of ischemia/reperfusion.
Kilgore
K S
KS
Department of Pharmacology, University of Michigan Medical School, Ann Arbor, USA.
Tanhehco
E J
EJ
Park
J L
JL
Naylor
K B
KB
Anderson
M B
MB
Lucchesi
B R
BR
D000818:Animals; D002448:Cell Adhesion / Q000187:drug effects; D019695:Glycyrrhizic Acid / Q000627:therapeutic use*; D006801:Humans; D007150:Immunohistochemistry; D007958:Leukocyte Count; D009203:Myocardial Infarction / Q000188:drug therapy*; D009504:Neutrophils / Q000187:drug effects; D019007:P-Selectin / Q000032:analysis; D009195:Peroxidase / Q000378:metabolism; D011817:Rabbits
D019007:P-Selectin; D019695:Glycyrrhizic Acid; D009195:Peroxidase